Blood cancers

VIALE-C data support use of venetoclax in AML patients not eligible for intensive chemo

New clinical research supports the use of venetoclax plus low-dose cytarabine (LDAC) as a frontline treatment option for patients with acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. In the VIALE-C trial, led by haematologist Professor Andrew Wei, from The Alfred Hospital and Monash University in Melbourne, 211 patients were randomised to receive ...

Already a member?

Login to keep reading.

© 2021 the limbic